Long-Term Use of Ticagrelor in Patients with Coronary Artery Disease

Area of Science:

• Cardiology
• Pharmacology
• Clinical Medicine

Background:

• Ticagrelor is a P2Y₁₂ inhibitor used in patients with coronary artery disease (CAD).
• Long-term dual antiplatelet therapy (DAPT) strategies require careful consideration of efficacy and safety.
• The PEGASUS-TIMI-54 trial investigated extended ticagrelor use post-myocardial infarction (MI).

Purpose of the Study:

• To review the safety and effectiveness of long-term ticagrelor therapy in CAD patients.
• To evaluate the benefits and risks of extending DAPT with ticagrelor beyond one year.

Main Methods:

• Analysis of the PEGASUS-TIMI-54 trial data involving over 21,000 patients.
• Randomized controlled trial comparing ticagrelor (90 mg or 60 mg twice daily) versus placebo.
• Assessment of primary efficacy endpoints and bleeding events, including major, intracranial, and fatal bleeding.

Main Results:

• Both ticagrelor doses significantly reduced the primary efficacy endpoint compared to placebo.
• A significant increase in TIMI major bleeding was observed with ticagrelor treatment.
• No significant differences in intracranial hemorrhage or fatal bleeding rates were found across treatment groups.

Conclusions:

• Extended DAPT with ticagrelor beyond one year provides clear benefits in reducing thrombotic events for patients with prior MI.
• The benefits of ticagrelor extension must be weighed against an increased risk of clinically significant bleeding.
• Treatment duration for DAPT should be individualized based on each patient's specific thrombotic and bleeding risk profiles.